Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 1, 2008Seminars in Thrombosis and HemostasisOpen Access

Current and Future Prospects for Anticoagulant Therapy: Inhibitors of Factor Xa and Factor IIa

View Full Paper
Ask AI
Bookmark
Share

Key result

This review summarizes the results of dose-finding studies and ongoing clinical trials for indirect and direct oral inhibitors of factor Xa and IIa in the prevention and treatment of venous thromboembolism.

Population

Patients requiring prevention of venous thromboembolism after elective orthopedic surgery or treatment of…

Comparison

Indirect systemic and direct oral factor Xa… vs Heparins and vitamin K antagonists

Design

Review

Authors

JHJob HarenbergHeidelberg UniversityMWMartin WehlingGeneral / Preventive / Lipids

Discussion

Loading...

Member takes

Implication

This review summarizes the clinical development and dose-finding studies of novel oral anticoagulants (Factor Xa and IIa inhibitors) for the prevention and treatment of venous thromboembolism.

Structured PICO

P
Population
Patients requiring prevention of venous thromboembolism after elective orthopedic surgery or treatment of acute venous thromboembolism
I
Intervention
Indirect systemic and direct oral factor Xa inhibitors (idraparinux, rivaroxaban, apixaban) and direct oral factor IIa inhibitors (dabigatran)
C
Comparator
Heparins and vitamin K antagonists

This review summarizes the clinical development and dose-finding studies of novel oral anticoagulants (Factor Xa and IIa inhibitors) for the prevention and treatment of venous thromboembolism.

Cite This Study

Harenberg et al. (2008) conducted a review in Venous thromboembolism. Inhibitors of Factor Xa and Factor IIa (idraparinux, rivaroxaban, apixaban, dabigatran) was evaluated. This review summarizes the results of dose-finding studies and ongoing clinical trials for indirect and direct oral inhibitors of factor Xa and IIa in the prevention and treatment of venous thromboembolism.

synapsesocial.com/papers/6a89b163d89205768aeb4301https://doi.org/10.1055/s-2008-1066023

Topics

Atrial fibrillationPersistent AF managementAnticoagulation in AF
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pharmacology and Clinical Potential of Direct Thrombin Inhibitors2005 · 23 citations
  2. 2Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases2006 · 106 citations
  3. 3Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber2007 · 125 citations
  4. 4Pharmacokinetics and Pharmacodynamics of Ximelagatran2005 · 7 citations